YU78701A - Tretiranje neurotskih poremećaja - Google Patents

Tretiranje neurotskih poremećaja

Info

Publication number
YU78701A
YU78701A YU78701A YUP78701A YU78701A YU 78701 A YU78701 A YU 78701A YU 78701 A YU78701 A YU 78701A YU P78701 A YUP78701 A YU P78701A YU 78701 A YU78701 A YU 78701A
Authority
YU
Yugoslavia
Prior art keywords
treatment
neurotic disorders
disorder
anxiety disorder
neurotic
Prior art date
Application number
YU78701A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
H. Lundbeck A/S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU78701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S. filed Critical H. Lundbeck A/S.
Publication of YU78701A publication Critical patent/YU78701A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
YU78701A 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja YU78701A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08

Publications (1)

Publication Number Publication Date
YU78701A true YU78701A (sh) 2004-03-12

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
YU78701A YU78701A (sh) 1999-07-08 2000-07-07 Tretiranje neurotskih poremećaja

Country Status (38)

Country Link
US (6) US7271194B2 (enExample)
EP (4) EP1440689A3 (enExample)
JP (1) JP4773011B2 (enExample)
KR (1) KR100604176B1 (enExample)
CN (1) CN1198610C (enExample)
AR (1) AR021155A1 (enExample)
AT (1) ATE339955T1 (enExample)
AU (6) AU782514B2 (enExample)
BG (4) BG110466A (enExample)
BR (1) BR0011578A (enExample)
CA (4) CA2687392A1 (enExample)
CL (3) CL2008003939A1 (enExample)
CO (1) CO5190674A1 (enExample)
CY (1) CY1105806T1 (enExample)
CZ (1) CZ200270A3 (enExample)
DE (1) DE60030861T2 (enExample)
DK (1) DK1200081T3 (enExample)
EA (1) EA006555B1 (enExample)
ES (1) ES2272298T3 (enExample)
HK (1) HK1048069B (enExample)
HR (1) HRP20010820A2 (enExample)
HU (1) HUP0201791A3 (enExample)
IL (5) IL146131A0 (enExample)
IS (1) IS6137A (enExample)
ME (2) ME00032B (enExample)
MX (1) MXPA01011626A (enExample)
MY (1) MY143278A (enExample)
NO (4) NO329021B1 (enExample)
PL (1) PL352030A1 (enExample)
PT (1) PT1200081E (enExample)
SI (1) SI1200081T1 (enExample)
SK (1) SK82002A3 (enExample)
TR (4) TR200402276T2 (enExample)
TW (1) TWI232101B (enExample)
UA (1) UA77645C2 (enExample)
WO (1) WO2001003694A1 (enExample)
YU (1) YU78701A (enExample)
ZA (1) ZA200108856B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
AU2001281740B2 (en) 2000-07-21 2006-02-16 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
WO2003011278A1 (en) 2001-07-31 2003-02-13 H. Lundbeck A/S Crystalline composition containing escitalopram
US20040067963A1 (en) * 2002-07-08 2004-04-08 University Of Florida Methods to prevent or ameliorate trauma-related psychological disorders
MXPA05005772A (es) * 2002-12-23 2005-08-16 Lundbeck & Co As H Bromhidrato de escitalopram y un metodo para su preparacion.
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
PL1708790T3 (pl) * 2003-12-02 2010-10-29 Pharmaneuroboost N V Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7569605B2 (en) 2005-10-14 2009-08-04 Forest Laboratories Holdings Limited Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (enExample) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
EP1208838A3 (en) 1991-11-15 2003-07-09 Sepracor Inc. Pure S(+)isomer fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
WO1997006792A1 (en) 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
ATE221522T1 (de) * 1997-11-11 2002-08-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
WO2000002551A2 (en) 1998-07-13 2000-01-20 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
CA2337507A1 (en) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
WO2000023431A1 (en) * 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
HK1048122B (zh) * 1999-04-14 2005-01-14 H‧隆德贝克有限公司 製備西酞普蘭的方法
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6469064B2 (en) 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram

Also Published As

Publication number Publication date
IL170194A (en) 2010-05-31
AU2005202684B2 (en) 2009-01-15
NO20100335L (no) 2002-01-07
CA2373757A1 (en) 2001-01-18
CN1360501A (zh) 2002-07-24
KR20020015346A (ko) 2002-02-27
IL146131A (en) 2007-02-11
AR021155A1 (es) 2002-06-12
UA77645C2 (en) 2007-01-15
US20050101665A1 (en) 2005-05-12
AU2005202685A1 (en) 2005-07-14
US20040029956A1 (en) 2004-02-12
NO20100334L (no) 2002-01-07
CL2008003938A1 (es) 2009-05-22
AU2008264182A1 (en) 2009-01-29
CO5190674A1 (es) 2002-08-29
NO20100333L (no) 2002-01-07
TR200200014T2 (tr) 2002-05-21
EP1200081B1 (en) 2006-09-20
TR200402275T2 (tr) 2005-03-21
US20040029958A1 (en) 2004-02-12
WO2001003694A1 (en) 2001-01-18
DE60030861D1 (de) 2006-11-02
NO329021B1 (no) 2010-07-26
CA2687396A1 (en) 2001-01-18
CY1105806T1 (el) 2011-02-02
HK1048069A1 (en) 2003-03-21
BG106279A (bg) 2002-08-30
ME00032B (me) 2010-02-10
BR0011578A (pt) 2002-03-26
AU782514B2 (en) 2005-08-04
US7271194B2 (en) 2007-09-18
ZA200108856B (en) 2002-12-24
EA006555B1 (ru) 2006-02-24
BG110467A (en) 2010-01-29
MEP2508A (xx) 2010-02-10
US7265151B2 (en) 2007-09-04
DK1200081T3 (da) 2006-12-27
HRP20010820A2 (en) 2003-08-31
EP1440689A2 (en) 2004-07-28
US6960613B2 (en) 2005-11-01
EA200200137A1 (ru) 2002-06-27
US20070276035A1 (en) 2007-11-29
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
ATE339955T1 (de) 2006-10-15
AU5806100A (en) 2001-01-30
IS6137A (is) 2001-10-30
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (en) 2004-07-28
BG110468A (en) 2010-01-29
EP1440689A3 (en) 2004-08-25
AU2005202685B2 (en) 2009-01-15
TR200402277T2 (tr) 2005-01-24
US20040029957A1 (en) 2004-02-12
IL170193A (en) 2010-04-29
TR200402276T2 (tr) 2005-01-24
AU2005202686B2 (en) 2009-01-15
AU2005202686A1 (en) 2005-07-14
CL2008003939A1 (es) 2009-06-05
SK82002A3 (en) 2002-07-02
EP1440691A3 (en) 2004-08-25
HK1048069B (zh) 2005-12-16
JP4773011B2 (ja) 2011-09-14
EP1440690A3 (en) 2004-08-18
DE60030861T2 (de) 2007-05-03
EP1440690A2 (en) 2004-07-28
CA2687394A1 (en) 2001-01-18
IL170192A (en) 2010-04-29
CL2008003941A1 (es) 2009-05-22
IL146131A0 (en) 2002-07-25
US20020086899A1 (en) 2002-07-04
TWI232101B (en) 2005-05-11
CZ200270A3 (cs) 2002-04-17
BG110466A (en) 2010-01-29
MY143278A (en) 2011-04-15
PT1200081E (pt) 2007-01-31
CA2687392A1 (en) 2001-01-18
HUP0201791A3 (en) 2005-02-28
ES2272298T3 (es) 2007-05-01
KR100604176B1 (ko) 2006-07-25
CA2373757C (en) 2010-01-05
NO20020062D0 (no) 2002-01-07
EP1200081A1 (en) 2002-05-02
CN1198610C (zh) 2005-04-27
HUP0201791A2 (en) 2002-10-28
AU2008264188A1 (en) 2009-05-07
MXPA01011626A (es) 2002-06-04
PL352030A1 (en) 2003-07-28
JP2003504332A (ja) 2003-02-04

Similar Documents

Publication Publication Date Title
NO20100333L (no) Behandling av nevrotiske forstyrrelser
BR0209580A (pt) Derivados de ciclohexan-1, 4 diamina substituìdos
BR0206568A (pt) Novo método e composições para o tratamento local de doença de meniere, de zumbido no ouvido e/ou de perda de audição
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
DE69930375D1 (de) Xylitolzusammensetzungen zur behandlung der oberen atmungsorgane
PT888325E (pt) Novos amino acidos ciclicos como agentes farmaceuiticos
BR9917038A (pt) Composto, composição farmacêutica, método de modulação da atividade receptora de quimocinas, método de tratamento ou prevenção de doenças inflamatórias, método de tratamento ou prevenção de asma e método de tratamento ou prevenção de disfunções inflamatórias
TR200201004T2 (tr) Monoamin reuptake önleyicileri olarak biaril eter türevleri
BR0111898A (pt) Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
SE9802208D0 (sv) Novel compounds
BR0210650A (pt) Tablete, e, uso do mesmo
DE50110618D1 (de) Verwendung von MEK-Inhibitoren zur Herstellung eines Arzneimittels gegen Negativstrang-RNA-Viren Infektionen
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
DK1187832T3 (da) Aminoheterocycler, som er anvendelige som farmaceutiske midler
EA200501280A1 (ru) Применение эсциталопрама для лечения приступов паники
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
SE9802209D0 (sv) Novel compounds
DK0891326T3 (da) Nye D-vitaminanaloger
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
EA200501282A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA200501281A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
MA28174A1 (fr) Utilisation d'inhibiteurs de cathepsine k dans des maladies de la perte osseuse severe